U.S. markets closed
  • S&P 500

    -4.87 (-0.12%)
  • Dow 30

    +34.87 (+0.10%)
  • Nasdaq

    -20.95 (-0.18%)
  • Russell 2000

    +11.16 (+0.59%)
  • Crude Oil

    -0.88 (-1.08%)
  • Gold

    -3.80 (-0.21%)
  • Silver

    +0.51 (+2.25%)

    +0.0002 (+0.02%)
  • 10-Yr Bond

    -0.0230 (-0.65%)

    +0.0040 (+0.33%)

    -1.0160 (-0.75%)

    -16.30 (-0.10%)
  • CMC Crypto 200

    +2.91 (+0.72%)
  • FTSE 100

    -2.26 (-0.03%)
  • Nikkei 225

    -448.18 (-1.59%)

Autism Spectrum Disorder Therapeutics Market Size [2021-2028] | is Expected to be Worth USD 5.15 Billion

Autism Spectrum Disorder Therapeutics Market Key Companies Analyzed in this Report are Otsuka Holdings Co. Ltd. (Tokyo, Japan), Johnson & Johnson Services, Inc. (New Jersey, U.S.), AstraZeneca (Cambridge, U.K.), Pfizer Inc. (New York, U.S.), Allergan (Dublin, Ireland), Q BioMed Inc (New York, U.S.), Hopebridge, LLC. (Indiana, U.S.), Eli Lilly and Company (Indiana, U.S.)

Pune, India, Dec. 14, 2021 (GLOBE NEWSWIRE) -- The global Autism Spectrum Disorder Therapeutics market size is expected to be worth USD 5.15 billion by 2028. The market size was USD 3.62 billion in 2020 and USD 3.78 billion in 2021. The market is further projected to grow at a CAGR of 4.5% during the forecast period of 2021-2028. This information is provided by Fortune Business Insights™, in its report, titled, “Autism Spectrum Disorder Therapeutics Market, 2021-2028.”

According to our researchers, the increasing incidence of autism spectrum disorder worldwide combined with growing consciousness concerning the situation and the accessible choices for the treatment are the prominent aspects that are anticipated to fuel the autism spectrum disorder therapeutics industry demand during the mentioned time period. Furthermore, increasing financing by chief players in the R&D section for the introduction of operative drugs in order to cure the autistic condition is assessed to promote the market growth during the forecast period of 2021-2028.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/autism-spectrum-disorder-therapeutics-market-101207

Report Coverage


Forecast Period


Forecast Period 2021-2028 CAGR


2028 Value Projection

USD 5.15 billion

Base Year


Market Size in 2020

USD 3.62 billion

Historical Data for

2017 to 2019

No. of Pages


Segments covered

Type, Treatment Type, Drug Therapies, Region

Growth Drivers

Accelerated Product Sanctions for Treatment to Fuel Market Growth

Rising Occurrence of Autism Disorder to Fuel Growth in North America

Modest Demand for Drugs amid COVID-19 Assisted by Increasing Acceptance of Telehealth

The unparalleled pandemic situation at preliminary phases occasioned into the closure of majority of companies in the healthcare industry, resulting in a stoppage of deliveries. Moreover, termination of therapy centres and ASD-associated services led in a pause or rescheduling of therapy meetings for autistic children. Nevertheless, rising anxiety heights in ASD patients and the jeopardy of being infected by COVID-19, as these fall under susceptible groups concluded in high adoption of tele-healthcare services and systems by the family or caregivers of the patient.

Click here to get the short-term and long-term impacts of COVID-19 on this Market. Please visit: https://www.fortunebusinessinsights.com/industry-reports/autism-spectrum-disorder-therapeutics-market-101207


On the basis of type, the global market is classified into autistic disorder, Asperger syndrome, pervasive developmental disorder, and others.

Among them, the autistic disorder segment held a directing market share in the year 2020 owing to the huge occurrence of this condition type.
The global market is further categorized into communication & behavioural therapies and drug therapy in terms of the treatment type.

In terms of region, the market is segregated into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Quick Buy - Luxury Car Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101207

Drivers and Restraints:

Accelerated Product Sanctions for Treatment to Fuel Market Growth
Promptly rising frequencies of ASD patients universally is expected to increase the demand for operative therapy in order to treat the disorder. Moreover, regulatory officials are intentionally functioning to offer a positive signal for new products to commercialize robust therapeutics for the patients.

For instance, in 2018, F. Hoffmann-La Roche Ltd achieved FDA advance therapy title for its oral drug, Balovaptan in treating autism spectrum disorder, to be utilized to advance fundamental social interaction and communication among patients suffering with ASD. Therefore, quicker and hastened sanctions by the supervisory bodies is estimated to stimulate the market growth during the impending years.

Regional Insights:

Rising Occurrence of Autism Disorder to Fuel Growth in North America
North America held maximum autism spectrum disorder therapeutics market share and the size was worth USD 2.12 billion in 2020. The supremacy of this region is accredited to the rising occurrence of autism disorder across the U.S., joined with the increasing implementation and enrolment for treatment and therapies.

Europe has captured the second-largest market share spot on account of the elevated investments in R&D field for the formation of ASD drugs.
Asia Pacific is predicted to observe maximum CAGR owing to the budding demand for operative autism spectrum disorder therapeutics methods combined with the growing development of healthcare infrastructure in order to inaugurate a totally-equipped therapy facility for ASD patients.

List of the Companies Operating in the Market:

  • Otsuka Holdings Co. Ltd. (Tokyo, Japan)

  • Johnson & Johnson Services, Inc. (New Jersey, U.S.)

  • AstraZeneca (Cambridge, U.K.)

  • Pfizer Inc. (New York, U.S.)

  • Allergan (Dublin, Ireland)

  • Q BioMed Inc (New York, U.S.)

  • Hopebridge, LLC. (Indiana, U.S.)

  • Eli Lilly and Company (Indiana, U.S.)

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/autism-spectrum-disorder-therapeutics-market-101207

Global Luxury Car Market Segmentation:

By Type:

  • Autistic Disorder

  • Asperger Syndrome

  • Pervasive Developmental Disorder

  • Others

By Treatment Type:

  • Communication & Behavioral Therapies

  • Drug Therapies

By Geography:

  • North America (USA, Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs